MSLN and cholangiocarcinoma: The overexpression of MSLN in triple-negative breast cancer (TNBC) [14,15], ovarian cancer [12], lung adenocarcinoma [21,22], cholangiocarcinoma [31] and pancreatic cancer [17,18] is related to poor prognosis.